“Tumor Suppressor Gene TP53 Mutated in 90 Percent of Most Common Childhood Bone Tumor,” St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center
The St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project found mutations in the tumor suppressor gene TP53 in 90 percent of osteosarcomas, suggesting the alteration plays a key role early in development of the bone cancer. The research was published Thursday online ahead of print in the journal Cell Reports. Authors from this story also represent The University of Texas MD Anderson Cancer Center and Siteman Cancer Center at Barnes-Jewish Hospital and Washin... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - April 3, 2014 Category: Cancer & Oncology Source Type: news
Tumor suppressor gene TP53 mutated in 90 percent of most common childhood bone tumor
St. Jude Children’s Research Hospital—Washington University Pediatric Cancer Genome Project finds TP53 gene is altered in nearly all osteosarcomas; results help explain how tumors withstand radiation therapy. (Michael Dyer, PhD, and Jinghui Zhang, PhD) (Source: St. Jude Children's Research Hospital)
Source: St. Jude Children's Research Hospital - April 3, 2014 Category: Pediatrics Source Type: news
[Podcast] Science Signaling Podcast: 21 January 2014
Therapies that interfere with signaling by the secreted factor ANGPTL2 may decrease the likelihood of osteosarcoma metastasis. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - January 21, 2014 Category: Science Authors: Yuichi Oike and Annalisa M. VanHook Source Type: news
[Research Article] The Secreted Protein ANGPTL2 Promotes Metastasis of Osteosarcoma Cells Through Integrin a51, p38 MAPK, and Matrix Metalloproteinases
Preventing signaling by ANGPTL2, which is stimulated by the tumor microenvironment, could inhibit metastasis. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - January 21, 2014 Category: Science Authors: Haruki Odagiri, Tsuyoshi Kadomatsu, Motoyoshi Endo, Tetsuro Masuda, Masaki Suimye Morioka, Shigetomo Fukuhara, Takeshi Miyamoto, Eisuke Kobayashi, Keishi Miyata, Jun Aoi, Haruki Horiguchi, Naotaka Nishimura, Kazutoyo Terada, Toshitake Yakushiji, Ichiro Ma Source Type: news
Boy who lost leg to cancer first child in UK to get robot leg
Eddy Parry, 5, from Derby, had to have his leg amputated after he developed a form of bone cancer called osteosarcoma. (Source: the Mail online | Health)
Source: the Mail online | Health - October 21, 2013 Category: Consumer Health News Source Type: news
Eleison obtains EU orphan drug designation for osteosarcoma drug
Eleison Pharmaceuticals received orphan drug designation from the European Commission (EC) for ILC (inhaled lipid-complexed gisplatin), for the treatment of osteosarcoma, a type of bone cancer. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 8, 2013 Category: Pharmaceuticals Source Type: news
Cancer patients could benefit from the combining of Chinese and Western medicine
Combining traditional forms of Chinese and Western medicine could offer new hope for developing new treatments for liver, lung, colorectal cancers and osteosarcoma of the bones. Experts from Cardiff University's School of Medicine have joined forces with Peking University in China to test the health benefits of a traditional Chinese medicine. The team also set-out to examine how by combining it with more traditional methods like Chemotherapy could improve patient outcomes and potentially lead to the development of new cancer treatments and therapies... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 1, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news
Combining Chinese and Western medicine could lead to new cancer treatments
(Cardiff University) Combining traditional forms of Chinese and Western medicine could offer new hope for developing new treatments for liver, lung, colorectal cancers and osteosarcoma of the bones. Experts from Cardiff University's School of Medicine have joined forces with Peking University in China to test the health benefits of a traditional Chinese medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 27, 2013 Category: Global & Universal Source Type: news
The worst bone tumors not found to be driven by pathways activated in most K9 bone tumors
Many cancers show inappropriate activation of a cell signaling pathway called NOTCH. In the developing body, NOTCH tells brain cells to grow and proliferate. It should be quiet in the adult body, but cancers restart NOTCH to drive their own growth, far and beyond the rate of healthy tissues. A Colorado State University and University of Colorado Cancer Center study expected to find NOTCH signaling elevated in K9 osteosarcoma samples, gathered from patients at the CSU Flint Animal Cancer Center... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 26, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news
Pathways activated in most K9 bone tumors not driving the worst bone tumors
(University of Colorado Denver) CU Cancer Center and CSU Flint Animal Cancer Center study shows NOTCH signaling was elevated in K9 osteosarcoma, but aspects of Notch signaling were noticeably deactivated in the worst cancers. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - July 23, 2013 Category: Global & Universal Source Type: news
